• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT MEDICAL SJM TRIFECTA VALVE; HEART-VALVE, NON-ALLOGRAFT TISSUE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT MEDICAL SJM TRIFECTA VALVE; HEART-VALVE, NON-ALLOGRAFT TISSUE Back to Search Results
Catalog Number UNK SJM TRIFECTA VALVE
Device Problem Degraded (1153)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 02/09/2023
Event Type  malfunction  
Manufacturer Narrative
Literature review: "comparison of in-hospital outcomes and long-term survival for valve-in-valve transcatheter aortic valve replacement versus the benchmark native valve transcatheter aortic valve replacement procedure" investigation is not yet complete.A follow-up report will be submitted with all additional relevant information.
 
Event Description
The article, "comparison of in-hospital outcomes and long-term survival for valve-in-valve transcatheter aortic valve replacement versus the benchmark native valve transcatheter aortic valve replacement procedure", was reviewed.The article presented a retrospective, single center study on evaluate the efficacy, safety, and long-term survival outcomes of valve-in-valve transcatheter aortic valve replacement (viv-tavr) compared with the benchmark native valve transcatheter aortic valve replacement (nv-tavr).Devices mentioned in the article were mitroflow, carpentier edwards, st jude trifecta, hancock, and mosaic.The article concluded that viv-tavr shares the safety and efficacy profile of nv-tavr.It also represents a better early outcome but a higher non-significant long-term mortality rate.[the primary and corresponding author was didier carrié, department of cardiology, toulouse university hospital, toulouse, france, with carrie.Didier@chu-toulouse.Fr] the time frame of the study was from january 2016 and january 2020.A total of 1658 patients were included in the study, 69 patients underwent viv-tavr for failed surgical prosthesis and 1589 patients underwent tavr for native valve.Of the 69 patients who underwent viv, 6 patients (8.7%) had received an abbott device.The average age was 83.9 years and the average gender was female.Comorbidities included dyslipidemia, diabetes mellitus, arterial hypertension, smoking, chronic lung disease, atrial fibrillation, prior stroke, prior myocardial infarction, prior coronary artery bypass graft, percutaneous coronary intervention.
 
Manufacturer Narrative
B3 - date of event is estimated.D4 - the udi number is not known as the part and lot numbers were not provided the additional patient effects reported in the article are captured under a separate medwatch report.Summarized patient outcomes/complications of comparison of in-hospital outcomes and long-term survival for valve-in-valve transcatheter aortic valve replacement versus the benchmark native valve transcatheter aortic valve replacement procedure were reported in a research article in a subject population with multiple co-morbidities including dyslipidemia, diabetes mellitus, arterial hypertension, smoking, chronic lung disease, atrial fibrillation, prior stroke, prior myocardial infarction, prior coronary artery bypass graft, percutaneous coronary intervention.Some of the complications reported were surgical intervention, hospitalization, acute heart failure, acute kidney injury, bleeding, and general structural valve deterioration these complications are anticipated for the procedure and subject population.A more comprehensive assessment could not be performed as the event was non-contemporaneously reported through a literature review and no device or individual patient information was received for analysis.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SJM TRIFECTA VALVE
Type of Device
HEART-VALVE, NON-ALLOGRAFT TISSUE
Manufacturer (Section D)
ABBOTT MEDICAL
5050 nathan lane n
plymouth MN 55442
Manufacturer (Section G)
ST. JUDE MEDICAL #3014918977
edificio #44 calle 0, ave. 2
el coyol alajuela 1897- 4050
CS   1897-4050
Manufacturer Contact
karen krouse
5050 nathan lane n
plymouth, MN 55442
6517565400
MDR Report Key18841159
MDR Text Key337105298
Report Number2135147-2024-01003
Device Sequence Number1
Product Code LWR
Combination Product (y/n)N
Reporter Country CodeFR
PMA/PMN Number
P100029
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Literature,Health Professional
Reporter Occupation Physician
Type of Report Initial,Followup
Report Date 04/09/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received03/05/2024
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Catalogue NumberUNK SJM TRIFECTA VALVE
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received03/26/2024
Was Device Evaluated by Manufacturer? No
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
-
-